Adil Daud, MD, compares the roles of immunotherapy versus dabrafenib plus trametinib targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.
Adil Daud, MD, a clinical professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco and director of Melanoma Clinical Research at the UCSF Helen Diller Family Comprehensive Cancer Center, compares the roles of immunotherapy versus dabrafenib (Tafinlar) plus trametinib (Mekinist) targeted therapy combinations in patients with advanced melanoma. The latter combination is appropriate and even preventative in select patients, but the decision between checkpoint immune therapy and immunotherapy comes down to what is best for each patient.
There are pros and cons to either treatment, says Daud. On one hand, patients can receive an oral treatment with a greater incidence of adverse events (AEs) that are more reversible. However, patients also have access to a treatment with a lower incidence of AEs that may be long-lasting and irreversible.
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More